TrialInternational journal of clinical oncology2024

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

Kiyotaka Yoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.